Skip to main content

Table 6 Univariate and multivariate analysis of different prognostic factors for progression free survival

From: Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center

Variable

n

Univariate Analysis

Multivariate analysis

Hazard Ratio (HR)

p

95% CI

HR

p

95% CI

Sex

 Female

158

1.03

0.787

0.78–1.36

   

 Male

219

      

Elderly

  > 65 yrs

33

0.75

0.243

0.46–1.2

   

  ≤ 65 yrs

344

      

Young

  ≤ 40 yrs

144

1.3

0.051

0.99–1.73

   

  > 40 yrs

233

      

ECOG

  ≥ 2

89

1.58

0.005

1.15–2.17

1.5

0.032

1.03–1.6

 0–1

223

      

Upfront

 Metastasis

256

1.22

0.182

0.91–1.63

   

 Relapsed

121

      

Hb (g/dl)

  < 10.8

165

1.48

0.006

1.12–1.96

1.14

0.44

0.8–1.6

  ≥ 10.8

156

      

CEA

 High

228

1.66

0.008

1.14–2.42

1.80

0.005

1.2–2.7

 Normal

65

      

Albumin(g/dl)

  < 3.5

54

1.49

0.043

1.01–2.20

1.26

0.309

0.8–1.96

  ≥ 3.5

263

      

Sidedness

 Left

285

1.06

0.71

0.76–1.48

   

 Right

75

      

Grade

 Poorly

19

1.60

0.12

0.87–2.9

   

 Moderately / Well

304

      

Morphology

 Signet / Mucinous

108

1.16

0.33

0.86–1.56

   

 Adenoca NOS

216

      

SAP

 High

11

1.67

0.216

0.73–3.82

   

 Normal

296

      

No of organs involved

  ≥ 2

90

1.3

0.09

0.95–1.80

   

 1

287

      

Liver metastasis

 Yes

161

1.08

0.573

0.82–1.42

   

 No

216

      

Peritoneum metastasis

 Yes

117

1.13

0.40

0.84–1.52

   

 No

300

      

No of liver Metastasis

  > 3

89

1.17

0.475

0.75–1.85

   

  ≤ 3

51

      

CT

 Irinotecan

90

1.25

0.162

0.91–1.72

   

 Oxaliplatin

247

      
  1. CT Chemotherapy, Hb hemoglobin, ECOG Eastern Cooperative Oncology group, CEA carcinoembryonic antigen, High CEA > 5 ng/ml, SAP Serum Alkaline Phosphate, CI Confidence interval, HR Hazard Ratio
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us